Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenanc...( NEW YORK Dec. 19 /- Intra-Cellula...),Health

NEW YORK, Dec. 19 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI) presented preclinical data on ITI-007, its first in class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) at a major medical meeting last week. The Company is developing ITI-007 for the treatment of schizophrenia and other related psychiatric conditions.

In this presentation, ITI-007 was shown to possess a unique pharmacologic profile, unlike any other existing antipsychotic drug. As a dopamine protein phosphorylation modulator, ITI-007 normalizes brain dopamine activity. At much lower doses and concentrations, ITI-007 selectively blocks 5HT2A receptors. Both of these actions are important for antipsychotic drug action.

"We believe the large separation between activity at dopamine and serotonin receptors will allow a personalized approach to patient treatment for schizophrenia providing an ability to 'dial-in' the optimal D2 receptor occupancy on an individual basis. This personalized approach will allow physicians to tailor doses to achieve optimal antipsychotic efficacy without inducing motoric or other side effects," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies.

In vivo, ITI-007 acted as a partial agonist at pre-synaptic dopamine receptors. For example, ITI-007 provoked an intracellular phosphorylation pattern consistent with the activity of a partial agonist at pre-synaptic dopamine receptors, thereby preserving normal dopamine metabolism. Furthermore, in the prefrontal cortex, a brain region profoundly affected in patients with schizophrenia, ITI-007's effects on extracellular concentrations of dopamine were consistent with a partial dopamine agonist profile.

The Company's presentation demonstrated ITI-007 also has an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disorders.

ITI's CNSProfile(TM) has shown, u
'/>"/>